Concepedia

Publication | Open Access

The pan‐caspase inhibitor Emricasan (<scp>IDN</scp>‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis

DOIFull Paper Access

280

Citations

57

References

2014

Year

Fernando Javier Barreyro, Silvia Holod, Paola Finocchietto, Alejandra Camino, Jorge B. Aquino, Alejandra Avagnina, Marı́a C. Carreras, Juan J. Poderoso, Gregory J. Gores
Liver International

Abstract

In conclusion, these data demonstrate that in a murine model of NASH, liver injury and fibrosis are suppressed by inhibiting hepatocytes apoptosis and suggests that Emricasan may be an attractive antifibrotic therapy in NASH.

References

YearCitations

Page 1